论文部分内容阅读
目的 观察国产新药万拉法新对肠易激综合征 (IBS)及其伴随的焦虑和抑郁症状的临床治疗效果。方法 选择 48例 IBS患者 ,随机分为治疗组和对照组 ,分别服用万拉法新及硝苯地平进行为期 4周的治疗 ,通过对 IBS各项症状的改善率和总体改善率评定观察治疗效果。同时采用 Zung编制的抑郁自评量表和焦虑自评量表进行评分观察治疗前后抑郁和焦虑的改善程度。结果 万拉法新对 IBS的治疗总体改善率为 80 % ,对照组为 5 2 .17% (P<0 .0 5 )。万拉法新治疗前后焦虑和抑郁的改善程度经检验均有统计学意义 (P<0 .0 1)。结论 单独应用万拉法新对 IBS的总体治疗效果优于硝苯地平组 ,对改善伴随的焦虑和抑郁症状有明显的疗效。
Objective To observe the clinical effect of homemade domesticated venlafaxine on irritable bowel syndrome (IBS) and its accompanying anxiety and depression symptoms. Methods Forty-eight patients with IBS were randomly divided into treatment group and control group. The patients were treated with venlafaxine and nifedipine for 4 weeks, and the treatment effect was observed by evaluating the improvement rate and overall improvement rate of each symptom of IBS . At the same time using Zung prepared self-rating depression scale and anxiety self-rating scale score observed before and after treatment to reduce the degree of depression and anxiety. Results The overall improvement rate of venlafaxine to IBS was 80% and that of control group was 52.17% (P <0.05). Venlafaxine treatment before and after treatment to improve the degree of anxiety and depression were tested statistically significant (P <0. 01). Conclusions The single treatment of venlafaxine is superior to the nifedipine group in overall treatment of IBS and has obvious curative effect on the improvement of accompanying anxiety and depressive symptoms.